Cardiol Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CRDL Nasdaq 2830 www.cardiolrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cardiol Therapeutics Inc.

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial - Aug 12th, 2026 6:01 am
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference - Aug 5th, 2026 5:27 am
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association - Jul 14th, 2026 5:27 am
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit - Jul 9th, 2026 5:27 am
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders - Jun 25th, 2026 5:27 am
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT - Jun 23rd, 2026 5:27 am
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation - May 15th, 2026 10:22 am
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - May 14th, 2026 5:27 am
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - May 7th, 2026 5:27 am
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - Apr 28th, 2026 5:27 am
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise - Apr 15th, 2026 4:15 am
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart - Apr 14th, 2026 5:27 am